The recent correction makes the stock a very compelling buy.
The company is operating in an industry which has severe headwinds where the large players are taking a beat.
However, the bet is extremely favourable (imo) as it operates in very lucrative and growth industries like * Healthcare, Life Sciences, BFSI, Retail Manufacturing, and TMT across key geographies. Aiming to reach $1.5 Billion revenue by FY26.
Valuations are coming down and increasing the Risk Reward Ratio
Subscribe To Our Free Newsletter |